Interestingly, patients with EGFR-mutated NSCLC experienced similar outcomes following treatment with the EGFR inhibitor osimertinib compared with pemetrexed chemotherapy; however, total TOT was significantly longer with osimertinib compared with pemetrexed (Fig. 4C and D). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.